Semaglutide in Canada: The Complete Guide to Ozempic & Wegovy

Semaglutide is the active molecule in both Ozempic and Wegovy - two medications that have become synonymous with a new era in obesity treatment. Originally developed by Novo Nordisk for type 2 diabetes, semaglutide's remarkable weight-loss effects in clinical trials prompted Health Canada to approve a higher-dose formulation specifically for chronic weight management.

How Semaglutide Works

Semaglutide is a GLP-1 receptor agonist - a synthetic analogue of glucagon-like peptide-1, a hormone produced in the gut after eating. By mimicking and prolonging GLP-1 signalling, semaglutide produces several interconnected effects:

• Appetite suppression: Acts on hypothalamic receptors to reduce hunger signals and food cravings
• Delayed gastric emptying: Food leaves the stomach more slowly, extending feelings of fullness
• Glucose regulation: Stimulates insulin release in response to meals; reduces glucagon secretion
• Reduced "food noise": Many patients report a quieting of the constant preoccupation with food that makes dieting psychologically exhausting

Unlike older appetite suppressants that worked primarily as stimulants or serotonin modulators, semaglutide works through a pathway the body already uses - which is why its effects feel natural to most patients and its long-term safety profile is favourable.

What the Clinical Evidence Shows

The STEP (Semaglutide Treatment Effect in People with Obesity) trial programme is the most comprehensive weight-management drug trial programme ever conducted. Key findings:

• STEP 1: Non-diabetic adults on 2.4 mg semaglutide lost an average 14.9% of body weight over 68 weeks vs. 2.4% on placebo
• STEP 2: Adults with type 2 diabetes lost an average 9.6% - still dramatically better than any prior medication
• STEP 4: Patients who discontinued after achieving weight loss regained approximately two-thirds of lost weight within a year, underscoring obesity as a chronic condition requiring ongoing management
• SELECT trial (2023): Semaglutide 2.4 mg reduced major cardiovascular events by 20% in adults with overweight/obesity and established cardiovascular disease - a landmark finding that expanded its clinical relevance far beyond aesthetics

Health Canada Approval

Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) was approved in 2018 for the treatment of type 2 diabetes mellitus in adults. It is widely prescribed off-label for weight management.

Wegovy (semaglutide 2.4 mg) received Health Canada approval in November 2021 specifically for chronic weight management in adults with:

• BMI ≥ 30 kg/m², or
• BMI ≥ 27 kg/m² plus at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease)

Rybelsus (oral semaglutide, 3 mg / 7 mg / 14 mg) is approved for type 2 diabetes. See our Oral GLP-1 guide for details.

Generic Semaglutide - The Game-Changer

In a significant milestone for Canadian patients, Health Canada approved two generic versions of semaglutide in 2025:

• Dr. Reddy's Laboratories - Indian pharmaceutical giant, one of the world's largest generic producers
• Apotex - A Canadian company, making this a domestic success story

Canada became the first G7 nation to approve generic semaglutide. Generics typically cost 45–90% less than brand-name equivalents. Exact retail pricing was being established at press time, but this development promises to significantly expand affordability over 2025–2026.

Who Qualifies for Semaglutide in Canada?

Eligibility depends on the indication:

• For diabetes (Ozempic): Diagnosed type 2 diabetes mellitus; no contraindications
• For weight management (Wegovy): BMI ≥ 30, or BMI ≥ 27 with a weight-related comorbidity
• Off-label use: Many physicians prescribe Ozempic for weight management in patients outside the strict Wegovy criteria - particularly those with BMI 25–30 and significant health risks

Absolute contraindications include: personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN2), current pregnancy, and known hypersensitivity to semaglutide.

How to Get a Semaglutide Prescription in Canada

Getting prescribed semaglutide in Canada is more accessible than many patients expect - particularly through online virtual care. Three main pathways exist:

1. Your family physician: The traditional route - potentially the most seamless if your GP is familiar with GLP-1 medications and comfortable prescribing them. Wait times and prescribing habits vary widely by physician and province.
2. Online virtual care: Platforms like Felix Health connect you with a licensed Canadian physician online. You complete a medical intake form, a physician reviews and responds within hours, and if appropriate, issues a prescription that can be delivered to your home. This is the most common way Canadians now order semaglutide online - faster and more convenient than waiting for an in-person appointment.
3. Obesity specialist / endocrinologist: For complex cases or when a GP referral is required. Often involves a longer wait but provides more comprehensive metabolic management.

Side Effects

Most side effects are gastrointestinal and dose-dependent. They are managed through the standard slow dose-escalation protocol (starting at 0.25 mg weekly and titrating up every 4 weeks):

• Nausea - most common (~44% in STEP trials); usually improves after weeks 4–8
• Vomiting - less common; slow titration and eating smaller meals helps
• Diarrhea or constipation
• Fatigue - especially early in treatment
• Reduced appetite - intentional effect, but can feel extreme initially

Rare but important concerns to discuss with your provider:

• Pancreatitis (seek care for severe, persistent abdominal pain)
• Gallbladder disease (slightly elevated risk; gallstones more common with rapid weight loss)
• Thyroid: animal data shows increased C-cell tumours - avoid in patients with MTC/MEN2 personal or family history

Cost of Semaglutide in Canada

Semaglutide is a prescription obesity medication, and pricing varies significantly by brand, dose, and province. Without insurance, Ozempic typically costs $200–$450 per month depending on dose and province. Wegovy runs approximately $380–$430 per month nationally. See our full province-by-province cost breakdown →

Coverage under provincial drug plans is mainly limited to Ozempic for diagnosed type 2 diabetes. Wegovy for weight management alone is generally not covered by provincial plans as of 2025, though private employer benefits increasingly include it. See our insurance coverage guide →

Frequently Asked Questions

Can I buy semaglutide online in Canada?

You cannot buy semaglutide over the counter - it requires a valid prescription from a licensed physician. However, you can get that prescription online through virtual care platforms that operate in Canada. A physician reviews your intake form and, if you qualify, issues a prescription that can be filled and shipped to your home. This makes it straightforward to get semaglutide injections in Canada without visiting a clinic in person.

Does Ozempic work if I don't have diabetes?

Yes. Semaglutide's weight-loss mechanism operates independently of blood-sugar effects. Wegovy clinical trials enrolled non-diabetic adults and showed comparable results. Many non-diabetic Canadians are prescribed Ozempic off-label or Wegovy on-label for weight management.

Will I regain weight when I stop?

Most patients regain significant weight after stopping - this is not a failure. It reflects the chronic, biological nature of obesity. Many clinicians now prescribe semaglutide long-term, similar to antihypertensives or statins.

Is it covered by provincial drug plans?

Coverage varies. Ontario ODB, BC PharmaCare, and other provincial plans cover Ozempic for type 2 diabetes under specific criteria. Wegovy for weight management is typically not covered provincially but is increasingly covered by private insurance. See our insurance guide for details.

Can I use semaglutide while pregnant or breastfeeding?

No. Semaglutide is contraindicated in pregnancy. Women of childbearing potential should use effective contraception during treatment and for at least 2 months after the last dose.